PT - JOURNAL ARTICLE AU - Wiens, Kirsten E. AU - Mawien, Pinyi Nyimol AU - Rumunu, John AU - Slater, Damien AU - Jones, Forrest K. AU - Moheed, Serina AU - Caflish, Andrea AU - Bior, Bior K. AU - Jacob, Iboyi Amanya AU - Lako, Richard Lino Loro AU - Guyo, Argata Guracha AU - Olu, Olushayo Oluseun AU - Maleghemi, Sylvester AU - Baguma, Andrew AU - Hassen, Juma John AU - Baya, Sheila K. AU - Deng, Lul AU - Lessler, Justin AU - Demby, Maya N. AU - Sanchez, Vanessa AU - Mills, Rachel AU - Fraser, Clare AU - Charles, Richelle C. AU - Harris, Jason B. AU - Azman, Andrew S. AU - Wamala, Joseph F. TI - Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study AID - 10.1101/2021.03.08.21253009 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.08.21253009 4099 - http://medrxiv.org/content/early/2021/03/12/2021.03.08.21253009.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.03.08.21253009.full AB - Background Relatively few COVID-19 cases and deaths have been reported through much of sub-Saharan Africa, including South Sudan, although the extent of SARS-CoV-2 spread remains unclear due to weak surveillance systems and few population-representative serosurveys.Methods We conducted a representative household-based cross-sectional serosurvey in Juba, South Sudan. We quantified IgG antibody responses to SARS-CoV-2 spike protein receptor-binding domain and estimated seroprevalence using a Bayesian regression model accounting for test performance.Results We recruited 2,214 participants from August 10 to September 11, 2020 and 22.3% had anti-SARS-CoV-2 IgG titers above levels in pre-pandemic samples. After accounting for waning antibody levels, age, and sex, we estimated that 38.5% (32.1 - 46.8) of the population had been infected with SARS-CoV-2. For each RT-PCR confirmed COVID-19 case, 104 (87-126) infections were unreported. Background antibody reactivity was higher in pre-pandemic samples from Juba compared to Boston, where the serological test was validated. The estimated proportion of the population infected ranged from 30.1% to 60.6% depending on assumptions about test performance and prevalence of clinically severe infections.Conclusions SARS-CoV-2 has spread extensively within Juba. Validation of serological tests in sub-Saharan African populations is critical to improve our ability to use serosurveillance to understand and mitigate transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Unity Studies Fund (World Health Organization Regional Office for Africa) and the African Development Bank Fund in addition to funding from the United States National Institutes of Health (R01 AI135115 to ASA and KEW) and the United States Centers for Disease Control and Prevention (U01CK000490 to RCC and JBH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:South Sudan Ministry of Health Ethics Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to are available within the manuscript or online in links provided. https://github.com/HopkinsIDD/juba-sars-cov-2-serosurvey